Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/47395
DC FieldValueLanguage
dc.contributor.authorFialho, Renata-
dc.contributor.authorPereira, Marco-
dc.contributor.authorHarrison, Neil-
dc.contributor.authorRusted, Jennifer-
dc.contributor.authorWhale, Richard-
dc.date.accessioned2018-02-02T11:29:26Z-
dc.date.available2018-02-02T11:29:26Z-
dc.date.issued2017-
dc.identifier.citationFialho, R., Pereira, M., Harrison, N., Rusted, J., & Whale, R. (2017). Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C. Psychiatry Research, 253, 150-157. doi:10.1016/j.psychres.2017.03.049por
dc.identifier.urihttp://hdl.handle.net/10316/47395-
dc.description.abstractIn this prospective study, we examined new-onset major depressive disorder (MDD) and the differential expression of depressive symptoms in a sample of 132 HCV mono-infected and 40 HIV/HCV co-infected patients initiating pegylated interferon-based treatment, including protease inhibitor therapy. The semi-structured clinical interview (SCID-I) was used to assess MDD. Severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale. Of the total sample, 60 patients (34.9%) developed SCID-I defined MDD during antiviral treatment. The proportion of HCV mono- and HIV/HCV patients developing MDD during treatment was not significantly different (37.9% vs. 25%; p=0.185). In both groups, there was a significant increase in HAMD total score from baseline to week 4, and a significant decrease between week 24 and 6 months post-treatment cessation. The greatest increase was observed in the symptoms of the neurovegetative syndrome. HCV mono-infected patients reported higher scores than co-infected patients, particularly impaired activity and somatic symptoms, but the differences were only significant at week 12. The finding that co-infected patients appear less vulnerable to the development of depressive symptoms during HCV treatment than HCV mono-infected patients warrants further exploration, including a thorough analysis of the biological and psychosocial factors associated with this emergence.por
dc.language.isoengpor
dc.rightsopenAccesspor
dc.subjectAdultpor
dc.subjectAntiviral Agentspor
dc.subjectCoinfectionpor
dc.subjectDepressive Disorder, Majorpor
dc.subjectDrug Therapy, Combinationpor
dc.subjectFemalepor
dc.subjectHIV Infectionspor
dc.subjectHepaciviruspor
dc.subjectHepatitis Cpor
dc.subjectHumanspor
dc.subjectInterferon-alphapor
dc.subjectMalepor
dc.subjectMiddle Agedpor
dc.subjectProspective Studiespor
dc.subjectRibavirinpor
dc.titleCo-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis Cpor
dc.typearticlepor
degois.publication.firstPage150por
degois.publication.lastPage157por
degois.publication.titlePsychiatry Researchpor
dc.relation.publisherversionhttp://www.psy-journal.com/article/S0165-1781(16)31874-1/fulltextpor
dc.peerreviewedyespor
dc.identifier.doi10.1016/j.psychres.2017.03.049-
degois.publication.volume253por
item.fulltextCom Texto completo-
item.languageiso639-1en-
item.grantfulltextopen-
crisitem.author.researchunitCenter for Research in Neuropsychology and Cognitive Behavioral Intervention-
crisitem.author.orcid0000-0002-6086-2329-
Appears in Collections:FPCEUC - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
2017 Depression Co_Infection HIV_HCV.pdf759.84 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

4
checked on May 29, 2020

WEB OF SCIENCETM
Citations

3
checked on May 29, 2020

Page view(s) 20

639
checked on Aug 4, 2020

Download(s)

98
checked on Aug 4, 2020

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.